Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 331-334

  Jubin, Ronald ^a   Murray, Michael G ^a   Howe, Anita Y M ^a   Butkiewicz, Nancy ^a   Hong, Zhi ^a   Lau, Johnson Y N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMANTADINE; HELICASE; PROTEINASE; RIMANTADINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; TRANSLATION REGULATION; VIRUS INHIBITION;

ADENOSINE TRIPHOSPHATASES; AMANTADINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; HEPACIVIRUS; PROTEIN BIOSYNTHESIS; RIMANTADINE; RNA HELICASES; RNA REPLICASE; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 0033972614     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315175     Document Type: Article

References (16)

1. 1. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventionl Therapy Group. N Engl J Med 1989; 321:1501-6.
2. 2. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
3. 3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.
4. 4. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-9.
5. 5. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42:1681-7.
6. 6. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991; 180: 617-24.
7. 7. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997; 25:1527-38.
8. 8. Feller JA, Lau JYN. Use of a dicistronic vector for the quantitation of HCV IRES activity. In: Lau JYN, ed. Hepatitis C protocols. Totowa, NJ: Humana Press, 1998:315-24.
9. 9. Sali DL, Ingram R, Wendel M, et al. Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex. Biochemistry 1998; 37: 3392-401.
10. 10. Jubin R, inventor; assignee, Schering Corp., Kenilworth, NJ. Assay for determining inhibitors of ATPase. US patent 5,759,795, 1998.
11. 11. Ferrari E. Wright-Minogue J, Fang JWS, Baroudy BM, Lau JYN, Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 1999; 73:1649-54.
12. 12. Physician's desk reference. 51 ed. Montvale, NJ: Medical Economics Publishing, 1997; 963-5:1013-5.
13. 13. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of I-adamantanamine (amantadine). Science 1964; 144:862-3.
14. 14. Lynch PJ, Peters MG, Lowell JA, Shenoy S, Howard TK, Caldwell CA. Amantadine therapy for recurrent hepatitis C after liver transplantation [abstract 737]. Hepatology 1998; 28(Suppl):347A.
15. 15. Senturk H, Mert A, Akdogan M, et al. Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b [abstract 842]. Hepatology 1998; 28(Suppl):373A.
16. 16. Brillanti S, Levantesi F, Foli M, Di Tomaso M, Bolondi L. Amantadine and rebetron exert a synergistic antiviral effect on HCV replication in interferon-alfa non-responders with chronic hepatitis C [abstract]. Gastroenterology 1999; 116(Suppl):A1193.